



Press release

Merger & Acquisition

19th of July, 2022



Larka provided Merieux with a **Commercial Due Diligence** to support its investment in **Janvier Labs.**



Advised by **Larka**

Larka is very pleased to announce it performed the Commercial Due Diligence to support Merieux on its investment in Janvier Labs, a European-leading BioPharma company offering translational research products and associated CRO services.

Merieux Participations 4 fund (MP4) – the Growth Buy-Out fund of Merieux Equity Partners – has signed a definitive agreement to acquire a minority stake in Janvier Labs. This investment will result in Merieux becoming the Lead Financial Investor of the Group – while the Janvier Family will remain the majority owner.

How Did Larka Support Merieux' Investment Process?

Acting as the Buy-Side Commercial Due Diligence advisor, Larka provided Merieux with **key insights and recommendations**, giving our M&A team a decisive role in the overall decision-making process, and in turn, the upcoming investment in Janvier by the Lyon-based Private Equity firm.

As for all of our Buy-Side and Sell-Side M&A services, this Commercial Due Diligence process leveraged Larka's extensive life sciences industry and biopharmaceuticals knowledge – in this case the **CRO and Research Model Services (RMS)** market – to provide Merieux with a comprehensive picture of Janvier Labs':

- Core value proposition within the translational research products and services landscape
- CRO and RMS market dynamics and market sizing
- Positioning in the competitive landscape
- Customer environment and market feedbacks
- Business Plan review and growth avenues



Larka's team has been instrumental in this operation. Their very deep understanding of the industry has helped us confirm our initial assessment of the market and of the quality of the asset. At the same time, their insightful recommendations helped us built a robust growth roadmap. Looking forward future projects with them.

Jean-François Billet
Managing Partner – Merieux Equity Partner

Contact Us

Pierre-Anthony Brioir
Senior Director
+33 650 630 286
pabrioir@larka.com

Adrien Chalmont
Senior Manager
+33 621 006 115
achalmont@larka.com

Discover Related Services

Commercial Due Diligence

[Visit website](#) ▶

Integrated Due Diligence

[Visit website](#) ▶

Operational Due Diligence

[Visit website](#) ▶

Technical Due Diligence

[Visit website](#) ▶



About Merieux Equity Partners

Mérieux Equity Partners ("MxEP") is an AMF-accredited management company dedicated to equity investments in the health and nutrition sector. MxEP actively supports entrepreneurs and companies with differentiated products and services, giving them privileged access to its sector expertise and international network.

For more information, please visit www.merieux-partners.com



About Janvier Labs

Janvier Labs is one of the world's leading players in translational research services. The Company offers innovative rodent research models for biomedical research as well as related services. Based near Laval and founded in 1960, Janvier Labs employs over 350 employees.

For more information, please visit www.janvier-labs.com



About Larka

Larka is a management consulting firm, exclusively dedicated to the Biotech and Pharma industry. We assist small Biotech or large Pharma companies, Contract Services Providers or Equipment Suppliers, Venture Capital or Private Equity firms, in their development or in managing complex situations. Active in Technical, Organizational, Commercial and Strategic operations, Larka has developed a unique combination of expertise which covers CMC & Outsourcing activities, Operational & Commercial excellence, Marketing & Sales, Corporate Strategy and M&A.

For more information, please visit www.larka.com



Larka